REV-ERB agonist raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-07-25. Anything still debated is marked as such rather than presented as settled.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
| Property | Value | Notes |
|---|---|---|
| Appearance | Off-white to pale yellow solid | Visual description varies with purity and source |
| Solubility | Soluble in DMSO and ethanol; poorly soluble in water | Organic stock solutions are common in research |
| Typical storage | -20 °C, desiccated, protected from light | Avoid repeated freeze-thaw cycles |
| Typical analytical method | LC-MS or HPLC-UV | Reference standards are needed for quantification |
| Molar mass | Approximately 437.9 g/mol | Calculated from the reported free-base formula |
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
The thyroid hormones function via a well-studied set of nuclear receptors, termed the thyroid hormone receptors. These receptors, together with corepressor molecules, bind DNA regions called thyroid hormone response elements (TREs) near genes. This receptor-corepressor-DNA complex can block gene transcription. Triiodothyronine (T3), which is the active form of thyroxine (T4), goes on to bind to receptors. The deiodinase catalyzed reaction removes an iodine atom from the 5′ position of the outer aromatic ring of thyroxine's (T4) structure. When triiodothyronine (T3) binds a receptor, it induces a conformational change in the receptor, displacing the corepressor from the complex. This leads to recruitment of coactivator proteins and RNA polymerase, activating transcription of the gene. Although this general functional model has considerable experimental support, there remain many open questions. More recently genetic evidence has been obtained for a second mechanism of thyroid hormone action involving one of the same nuclear receptors, TRβ, acting rapidly in the cytoplasm through the PI3K. This mechanism is conserved in all mammals but not fish or amphibians, and regulates brain development and adult metabolism. The mechanism itself parallels the actions of the nuclear receptor in the nucleus: in the absence of hormone, TRβ binds to PI3K and inhibits its activity, but when hormone binds the complex dissociates, PI3K activity increases, and the hormone bound receptor diffuses into the nucleus.
===== Efficacy ===== Many studies have shown that leuprorelin, goserelin and triptorelin are effective in suppressing sexual desires and increasing control against sex. Patients who were prescribed with these drugs have sexual thoughts less frequently and strongly.
The white, nonpigmented mats were found to be an autotrophic sulfur bacteria Beggiatoa species, and the orange mats possessed an unidentified non-chemosynthetic metabolism (MacDonald, 1998b). Heterotrophic species at seep sites are a mixture of species unique to seeps (particularly molluscs and crustacean invertebrates) and those that are a normal component from the surrounding environment. Carney (1993) first reported a potential imbalance that could occur as a result of chronic disruption. Because of sporadic recruitment patterns, predators could gain an advantage, resulting in exterminations in local populations of mussel beds. It is clear that seep systems do interact with the background fauna, but conflicting evidence remains as to what degree outright predation on some specific community components such as tubeworms occurs (MacDonald, 2002). The more surprising results from this recent work is why background species do not utilize seep production more than seems to be evident. In fact, seep-associated consumers such as galatheid crabs and nerite gastropods had isotopic signatures, indicating that their diets were a mixture of seep and background production. At some sites, endemic seep invertebrates that would have been expected to obtain much if not all their diet from seep production actually consumed as much as 50 percent of their diets from the background.
=== Main characters === Frank Poole: 3001's protagonist, Frank Poole has been revived by highly advanced medicine, a thousand years after being killed by HAL during the Discovery's original mission. Dr. Indra Wallace: A specialist on the history of the early twenty-first century, Wallace acts as Poole's cultural guide. Halman: a merging of the entities that were once HAL 9000 and Dave Bowman, Halman communicates with Poole at various points throughout the novel, warning Poole of the possibility that the monoliths may issue negative judgment against humanity.
When bacteria grow in anaerobic environments, the terminal electron acceptor is reduced by an enzyme called a reductase. E. coli can use fumarate reductase, nitrate reductase, nitrite reductase, DMSO reductase, or trimethylamine-N-oxide reductase, depending on the availability of these acceptors in the environment. Most terminal oxidases and reductases are inducible. They are synthesized by the organism as needed, in response to specific environmental conditions.
Sources: en.wikipedia.org
Specialized CaM kinases, such as the myosin light chain kinase that phosphorylates myosin, causing smooth muscles to contract. Multifunctional CaM kinases, such as the four isozymes of CaM kinase II, which play a role in neurotransmitter secretion, transcription factor regulation, and glycogen metabolism.
In addition to power and ground, these provide connections for data-in, data-out, clock and sometimes a strobe signal. These are connected in a daisy chain, which allows individual LEDs in a long LED strip light to be easily controlled by a microcontroller. Data sent to the first LED of the chain can control the brightness and color of each LED independently of the others. They are used where a combination of maximum control and minimum visible electronics are needed such as strings for Christmas and LED matrices. Some even have refresh rates in the kHz range, allowing for basic video applications. These devices are known by their part number (WS2812 being common) or a brand name such as NeoPixel. Filament An LED filament consists of multiple LED chips connected in series on a common longitudinal substrate that forms a thin rod reminiscent of a traditional incandescent filament. These are being used as a low-cost decorative alternative for traditional light bulbs that are being phased out in many countries. The filaments use a rather high voltage, allowing them to work efficiently with mains voltages. Often a simple rectifier and capacitive current limiting are employed to create a low-cost replacement for a traditional light bulb without the complexity of the low voltage, high current converter that single die LEDs need. Usually, they are packaged in bulb similar to the lamps they were designed to replace, and filled with inert gas at slightly lower than ambient pressure to remove heat efficiently and prevent corrosion.
For services to Business and to the UK Film Industry. Catherine Anne Goodman, LVO. Artist and Educator. For services to Art. Professor Roger James Goodman. Nissan Professor of Modern Japanese Studies and Warden, St. Antony's College, University of Oxford. For services to Social Science. Gayle Jean Margaret Gorman. Lately HM Chief Inspector and Chief Executive, Education Scotland. For services to Education and Charity. Gerard Arthur Georges Grech. Founder, Tech Nation and Managing Director, Founders at the University of Cambridge. For services to the Technology Sector. The Reverend Nicholas Glyn Paul Gumbel. Lately Vicar, Holy Trinity Brompton, London. For services to the Church of England. Paul Harris. Deputy Chief Executive Officer and Operations Director, HM Courts and Tribunals Service. For Public and Voluntary Service. Martin James Hewitt, QPM. Lately Chair, National Police Chiefs Council. For services to Policing. Professor Peter Michael Hollingsworth. Director of Science and Deputy Keeper, Royal Botanic Garden, Edinburgh. For services to Botanical Science. Karl James Hoods. Chief Digital and Information Officer, Department for Science, Innovation and Technology and Department for Energy Security and Net Zero. For services to Technology and to Education. Professor Andrew Lee Hopkins, FRS, FMedSci, FRSE. Chief Executive Officer, Exscientia. For services to Science and to Innovation. Christian Edward Johnston Horner, OBE. Team Principal and Chief Executive Officer, Red Bull Racing. For services to Motor Sport. Pauline Jean Howie, OBE.
CMS determined that this would not be practical and instead is working on publishing a brochure that will be distributed by surveyors to labs, published on the CMS CLIA Web site, and distributed at lab professional meetings. Few labs were the subject of a complaint each year from 2002 through 2004—significantly less than one complaint per lab per year. Concerns that labs can easily identify the lab workers who file complaints and lab workers' lack of familiarity with how to file a complaint may explain why so few laboratory workers report problems. Complaints are an important tool in detecting quality problems between lab surveys. For example, complaints about testing at a hospital lab were crucial because information had been concealed, complicating the detection of quality problems during the lab's surveys. As a result of a complaint, surveyors were able to substantiate inadequate calibration of testing equipment that could adversely affect patient care. Several of the AOs, such as CAP, require laboratories to post the complaint contact signs, but only in employee areas.
=== Depression === Some evidence supports the use of buprenorphine for depression. Buprenorphine/samidorphan, a combination product of buprenorphine and samidorphan (a preferential μ-opioid receptor antagonist), appears useful for treatment-resistant depression. A buprenorphine implant (developmental code name SK-2110) is under development by Shenzhen ScienCare Pharmaceutical in China for the treatment of refractory major depressive disorder.
Sources: en.wikipedia.org
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.
The compound is generally handled as light-sensitive and stored cold and dry. Stability in solution depends on solvent, concentration, and storage time. Specific degradation rates are not fully standardized.
Limited water solubility affects formulation for cell and animal studies. Organic co-solvents are often used to dissolve it. Precipitation can confound assay results if not controlled.
Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.